Boston Trust Walden Corp Has $85.82 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Boston Trust Walden Corp trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 355,955 shares of the medical instruments supplier’s stock after selling 25,493 shares during the period. Boston Trust Walden Corp’s holdings in Becton, Dickinson and Company were worth $85,821,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Nordea Investment Management AB lifted its holdings in Becton, Dickinson and Company by 277.3% during the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares in the last quarter. PineStone Asset Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after acquiring an additional 788,735 shares during the period. M&G Plc bought a new position in Becton, Dickinson and Company in the first quarter valued at about $173,692,000. First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of BDX stock traded down $0.49 on Friday, hitting $238.13. The stock had a trading volume of 1,001,988 shares, compared to its average volume of 1,380,241. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The company has a fifty day moving average price of $237.46 and a two-hundred day moving average price of $235.15. The firm has a market cap of $68.82 billion, a P/E ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the previous year, the firm earned $2.96 earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. As a group, analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BDX. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.